TWINSS extension
99 years and younger
All genders
This is a 1-year extension to the core TWINSS study, open only to eligible participants from the core study who, in the opinion of the Investigator, may potentially derive clinical benefit from continued administration of CFZ533 (iscalimab). The purpose is to provide additional safety and tolerability information and further explore …